


## PHARMACEUTICAL 2018

## G1 Therapeutics Inc. Rank 98 of 342







## PHARMACEUTICAL 2018

## G1 Therapeutics Inc. Rank 98 of 342



The relative strengths and weaknesses of G1 Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of G1 Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 124% points. The greatest weakness of G1 Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 126% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	104,661
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,704
Liabilities, Non-Current	79
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	847
Other Revenues	0
Property and Equipment	510
Research and Development	53,881
Selling, General and Administrative Expense	7,087

Output Variable	Value in 1000 USD
Assets	105,171
Liabilities	11,783
Expenses	60,968
Revenues	0
Stockholders Equity	93,388
Net Income	-60,121
Comprehensive Net Income	-60,121
Economic Capital Ratio	172%

